Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties

Ryo Kato, Masaya Iwamuro, Hidenori Shiraha, Shigeru Horiguchi, Emi Tanaka, Ken Matsumoto, Atsushi Ohyama, Hiroaki Sawahara, Teruya Nagahara, Daisuke Uchida, Koichiro Tsutsumi, Hiroyuki Okada

Research output: Contribution to journalArticle

Abstract

The γ-secretase inhibitor blocks Notch activity by preventing its cleavage at the cell surface. In the present study, the effect of the γ-secretase inhibitor on the viability of gastric cancer cells when administered in combination with cisplatin was investigated, with particular focus on CD44highLgr-5high cancer cells. The four gastric cancer cell lines, MKN45, MKN74, SC-6-JCK and SH-10-TC, were used for the experiments. In the MTT assay, treatment with 25 μM dipeptide γ-secretase inhibitor (DAPT) alone did not affect cell proliferation in any of the four cell lines. Gastric cancer cells subjected to combination treatment with DAPT and cisplatin exhibited decreased viability when compared with those treated with cisplatin alone. Flow cytometry was performed to evaluate the expression of cluster of differentiation (CD)-44 and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr-5), two cancer stem cell markers in gastric cancers. Treatment with cisplatin alone significantly increased the proportion of CD44highLgr-5high cells. However, the addition of DAPT to cisplatin reduced the CD44highLgr-5high fraction, suggesting that DAPT reduced the number of gastric cancer cells. In conclusion, the present study demonstrated the synergistic effects of DAPT in combination with cisplatin by decreasing the survival of gastric cancer cells. In addition, combination treatment with DAPT reduced the number of CD44highLgr-5high cells, which are thought to exhibit cancer stem cell properties. These results highlight the therapeutic potential of DAPT in gastric cancer treatment.

Original languageEnglish
Pages (from-to)5426-5432
Number of pages7
JournalOncology Letters
Volume16
Issue number4
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Amyloid Precursor Protein Secretases
Neoplastic Stem Cells
Dipeptides
Cisplatin
Stomach Neoplasms
Neoplasms
Cell Line
G-Protein-Coupled Receptors
Leucine
Flow Cytometry
Cell Proliferation

Keywords

  • Cancer stem cell
  • Gastric cancer
  • Notch pathway
  • γ-secretase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties. / Kato, Ryo; Iwamuro, Masaya; Shiraha, Hidenori; Horiguchi, Shigeru; Tanaka, Emi; Matsumoto, Ken; Ohyama, Atsushi; Sawahara, Hiroaki; Nagahara, Teruya; Uchida, Daisuke; Tsutsumi, Koichiro; Okada, Hiroyuki.

In: Oncology Letters, Vol. 16, No. 4, 01.10.2018, p. 5426-5432.

Research output: Contribution to journalArticle

@article{1bf7223075f54c0b844a9ff49a446a50,
title = "Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties",
abstract = "The γ-secretase inhibitor blocks Notch activity by preventing its cleavage at the cell surface. In the present study, the effect of the γ-secretase inhibitor on the viability of gastric cancer cells when administered in combination with cisplatin was investigated, with particular focus on CD44highLgr-5high cancer cells. The four gastric cancer cell lines, MKN45, MKN74, SC-6-JCK and SH-10-TC, were used for the experiments. In the MTT assay, treatment with 25 μM dipeptide γ-secretase inhibitor (DAPT) alone did not affect cell proliferation in any of the four cell lines. Gastric cancer cells subjected to combination treatment with DAPT and cisplatin exhibited decreased viability when compared with those treated with cisplatin alone. Flow cytometry was performed to evaluate the expression of cluster of differentiation (CD)-44 and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr-5), two cancer stem cell markers in gastric cancers. Treatment with cisplatin alone significantly increased the proportion of CD44highLgr-5high cells. However, the addition of DAPT to cisplatin reduced the CD44highLgr-5high fraction, suggesting that DAPT reduced the number of gastric cancer cells. In conclusion, the present study demonstrated the synergistic effects of DAPT in combination with cisplatin by decreasing the survival of gastric cancer cells. In addition, combination treatment with DAPT reduced the number of CD44highLgr-5high cells, which are thought to exhibit cancer stem cell properties. These results highlight the therapeutic potential of DAPT in gastric cancer treatment.",
keywords = "Cancer stem cell, Gastric cancer, Notch pathway, γ-secretase inhibitor",
author = "Ryo Kato and Masaya Iwamuro and Hidenori Shiraha and Shigeru Horiguchi and Emi Tanaka and Ken Matsumoto and Atsushi Ohyama and Hiroaki Sawahara and Teruya Nagahara and Daisuke Uchida and Koichiro Tsutsumi and Hiroyuki Okada",
year = "2018",
month = "10",
day = "1",
doi = "10.3892/ol.2018.9301",
language = "English",
volume = "16",
pages = "5426--5432",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Dipeptide γ-secretase inhibitor treatment enhances the anti-tumor effects of cisplatin against gastric cancer by suppressing cancer stem cell properties

AU - Kato, Ryo

AU - Iwamuro, Masaya

AU - Shiraha, Hidenori

AU - Horiguchi, Shigeru

AU - Tanaka, Emi

AU - Matsumoto, Ken

AU - Ohyama, Atsushi

AU - Sawahara, Hiroaki

AU - Nagahara, Teruya

AU - Uchida, Daisuke

AU - Tsutsumi, Koichiro

AU - Okada, Hiroyuki

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The γ-secretase inhibitor blocks Notch activity by preventing its cleavage at the cell surface. In the present study, the effect of the γ-secretase inhibitor on the viability of gastric cancer cells when administered in combination with cisplatin was investigated, with particular focus on CD44highLgr-5high cancer cells. The four gastric cancer cell lines, MKN45, MKN74, SC-6-JCK and SH-10-TC, were used for the experiments. In the MTT assay, treatment with 25 μM dipeptide γ-secretase inhibitor (DAPT) alone did not affect cell proliferation in any of the four cell lines. Gastric cancer cells subjected to combination treatment with DAPT and cisplatin exhibited decreased viability when compared with those treated with cisplatin alone. Flow cytometry was performed to evaluate the expression of cluster of differentiation (CD)-44 and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr-5), two cancer stem cell markers in gastric cancers. Treatment with cisplatin alone significantly increased the proportion of CD44highLgr-5high cells. However, the addition of DAPT to cisplatin reduced the CD44highLgr-5high fraction, suggesting that DAPT reduced the number of gastric cancer cells. In conclusion, the present study demonstrated the synergistic effects of DAPT in combination with cisplatin by decreasing the survival of gastric cancer cells. In addition, combination treatment with DAPT reduced the number of CD44highLgr-5high cells, which are thought to exhibit cancer stem cell properties. These results highlight the therapeutic potential of DAPT in gastric cancer treatment.

AB - The γ-secretase inhibitor blocks Notch activity by preventing its cleavage at the cell surface. In the present study, the effect of the γ-secretase inhibitor on the viability of gastric cancer cells when administered in combination with cisplatin was investigated, with particular focus on CD44highLgr-5high cancer cells. The four gastric cancer cell lines, MKN45, MKN74, SC-6-JCK and SH-10-TC, were used for the experiments. In the MTT assay, treatment with 25 μM dipeptide γ-secretase inhibitor (DAPT) alone did not affect cell proliferation in any of the four cell lines. Gastric cancer cells subjected to combination treatment with DAPT and cisplatin exhibited decreased viability when compared with those treated with cisplatin alone. Flow cytometry was performed to evaluate the expression of cluster of differentiation (CD)-44 and leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr-5), two cancer stem cell markers in gastric cancers. Treatment with cisplatin alone significantly increased the proportion of CD44highLgr-5high cells. However, the addition of DAPT to cisplatin reduced the CD44highLgr-5high fraction, suggesting that DAPT reduced the number of gastric cancer cells. In conclusion, the present study demonstrated the synergistic effects of DAPT in combination with cisplatin by decreasing the survival of gastric cancer cells. In addition, combination treatment with DAPT reduced the number of CD44highLgr-5high cells, which are thought to exhibit cancer stem cell properties. These results highlight the therapeutic potential of DAPT in gastric cancer treatment.

KW - Cancer stem cell

KW - Gastric cancer

KW - Notch pathway

KW - γ-secretase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85052389033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052389033&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.9301

DO - 10.3892/ol.2018.9301

M3 - Article

VL - 16

SP - 5426

EP - 5432

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -